Scholarlink

Background <p>Patients with diabetes mellitus and its complications are at increased risk for cardiovascular diseases. Semaglutide is efficacious for glycemic control and reducing the risk of major adverse cardiovascular outcomes. Although trials have provided data about cardiovascular outcomes with this agent, a meta-analysis regarding its cardiovascular safety and variations in outcomes according to sex, race and estimated glomerular filtration rate was necessary.</p> Materials and Methods <p>We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome. We assessed the quality of the RCTs using the Cochrane Risk of Bias tool and used the statistical software RevMan 5.4. The protocol for this review was registered on PROSPERO (CRD42024580784).</p> Results <p>Of 5387 articles, four RCTs were included. The risk of MACE with semaglutide was significantly lower in patients with established or a risk of cardiovascular disease (risk ratio [RR] 0.81; 95% confidence interval [CI] 0.74–0.88; <i>p</i> &lt; 0.00001). The risk of expanded MACE also reduced significantly with semaglutide (RR 0.80; 95% CI 0.75–0.86; <i>p</i> &lt; 0.00001). MACE risk reduction was significant in males (RR 0.78; 95% CI 0.70–0.87; <i>p</i> &lt; 0.00001) and in Asian (RR 0.61; 95% CI 0.44–0.83; <i>p</i> = 0.002) and white (RR 0.82; 95% CI 0.73–0.90; <i>p</i> = 0.0001) populations.</p> Conclusion <p>Semaglutide provides significant advantages in terms of lowering the risk of MACE and expanded MACE and could possibly be used as a crucial component of cardiovascular risk management, particularly in populations that respond well, such as men and Asian and white populations.</p> Registration <p>PROSPERO identifier number CRD42024580784.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis

  • 期刊论文

  • 发表日期：

    2025年3月19日

查看全文
  • Muhammad Hamayal,
  • Chaudhary Humayun Akhtar,
  • Naveed Ahmad,
  • Muhammad Awwab,
  • Warda Shahid,
  • Hasan Shaukat Abbasi,
  • Esha Nadeem,
  • Erum Siddiqui,
  • Wadana Zafar,
  • Saima Hussain

摘要

Background

Patients with diabetes mellitus and its complications are at increased risk for cardiovascular diseases. Semaglutide is efficacious for glycemic control and reducing the risk of major adverse cardiovascular outcomes. Although trials have provided data about cardiovascular outcomes with this agent, a meta-analysis regarding its cardiovascular safety and variations in outcomes according to sex, race and estimated glomerular filtration rate was necessary.

Materials and Methods

We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome. We assessed the quality of the RCTs using the Cochrane Risk of Bias tool and used the statistical software RevMan 5.4. The protocol for this review was registered on PROSPERO (CRD42024580784).

Results

Of 5387 articles, four RCTs were included. The risk of MACE with semaglutide was significantly lower in patients with established or a risk of cardiovascular disease (risk ratio [RR] 0.81; 95% confidence interval [CI] 0.74–0.88; p < 0.00001). The risk of expanded MACE also reduced significantly with semaglutide (RR 0.80; 95% CI 0.75–0.86; p < 0.00001). MACE risk reduction was significant in males (RR 0.78; 95% CI 0.70–0.87; p < 0.00001) and in Asian (RR 0.61; 95% CI 0.44–0.83; p = 0.002) and white (RR 0.82; 95% CI 0.73–0.90; p = 0.0001) populations.

Conclusion

Semaglutide provides significant advantages in terms of lowering the risk of MACE and expanded MACE and could possibly be used as a crucial component of cardiovascular risk management, particularly in populations that respond well, such as men and Asian and white populations.

Registration

PROSPERO identifier number CRD42024580784.